



BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com
CIN : L02423MP1993PLC007840

ANNEXURE I

Submission of Audited Financial Result by Companies Other than Banks

Part I

Statement of standalone Audited Result for the Quarter/ year ended 31/03/2020

(Rs in 000)

Particulars	Quarter ended			Year Ended	
	3 months ended (31-03-2020)	Preceding 3 months ended (31-12-2019)	Corresponding 3 months ended in the previous year (31-03-2019)	Year to date figures for current period ended (31-03-2020)	Year to date figures for previous period ended (31-03-2019)
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue From Operations					
Net sales or Revenue from Operations	30607	22518	22489	128151	129598
Other operating revenues	492	1126	1605	2331	2438
Total Revenue from operations (net)	31099	23644	24094	130482	132036
2 Expenses					
(a) Cost of materials consumed	16822	12922	12963	66779	68492
(b) Purchases of stock-in-trade	0	0	0	0	0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3078	-3654	-889	-700	1295
(d) Employee benefit expense	2600	2859	1893	9653	8455
(e) Finance costs	1385	604	-278	3210	1461
(f) Depreciation and amortisation expense	2504	2000	1120	6594	3241
(g) Other Expenses	10876	6938	8417	43367	41129
Total expenses	37265	21669	23226	128903	124073
3 Profit (loss) from operations before exceptional items and tax	-6166	1975	868	1579	7963
4 Exceptional items	0	0	0	0	0
5 Profit (loss) before tax	-6166	1975	868	1579	7963
6 Tax Expense					
Current tax	-1655	0	791	-355	2562
Deferred tax	705	1051	-958	1455	-506
Total Tax Expenses	-950	1051	-167	1100	2056
7 Net Profit (loss) for the period from continuing operations	-5216	924	1035	479	5907
8 Net Profit (loss) from discontinuing operations before tax	0	0	0	0	0
9 Tax Expense of discontinuing operations	0	0	0	0	0
10 Net Profit (loss) from discontinuing operations after tax	0	0	0	0	0
11 Net Profit (loss) for the Period	-5216	924	1035	479	5907
12 Other comprehensive income					
(i) Items that will not be reclassified to Statement of Profit and Loss	627	-44	-314	494	2703
(ii) Items that will be reclassified to Statement of Profit and Loss	0	0	0	0	0
Total Comprehensive Income	-4589	880	721	973	8610
14 Details of equity share capital					
Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000	50717.000
Face value of equity share capital	10.000	10.000	10.000	10.000	10.000
15 Earnings per share					
i Basic earnings per share before extraordinary items	-1.03	0.18	0.20	0.09	1.16
ii Diluted earnings per share before extraordinary items	-1.03	0.18	0.20	0.09	1.16

Notes to the Results:

- The above Financial Results for the quarter and year ended 31st March 2020 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Thursday 30th July 2020 and the financial result have been audited by the Statutory Auditors of the Company. The statutory Auditors have expressed an unmodified audit opinion on the results.
- This Statement is as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These audited financial results of the Company are prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (The Act) read with relevant Rules issued thereunder (Ind AS) and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI).
- The figures for the quarter ended March 31, 2020 and the quarter ended March 31, 2019 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditors of the Company.
- Figures for the previous periods have been regrouped, wherever necessary and minus figures are shown in brackets.
- Depreciation on fixed assets is provided on written down value method as per the estimated remaining useful life of assets.
- Revenue from Operations is net of GST.
- Earnings per share amount is shown in Rupees.
- The Company has identified "Pharmaceutical Industry" as the single operating segment for the continued operations in the standalone financial statements as per Ind AS 108 "Operating Segments".

For and on behalf of the Board of Directors of
BERYL DRUGS LIMITED

Sanjay Sethi
Sanjay Sethi
Managing Director
DIN 00090277

Date: 30th July 2020
Place: Indore